Poniard Pharmaceuticals, Inc. (PARD) Research

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and market introduction of cancer treatments. Its flagship product candidate, Picoplatin, is a platinum-based therapy targeting various cancer types, such as small cell lung, colorectal, prostate, and ovarian cancers. The company has advanced Picoplatin through several clinical stages, including a pivotal Phase III SPEAR trial for small cell lung cancer patients in a second-line treatment setting. Furthermore, Phase II studies investigated Picoplatin as an initial therapy for metastatic colorectal cancer and hormone-refractory prostate cancer. An early-stage Phase I trial also examined an oral formulation of Picoplatin for solid tumors. Founded in 1984 as NeoRx Corporation, the company rebranded to Poniard Pharmaceuticals, Inc. in September 2006 and operates from its base in Seattle, Washington.

Market snapshot

Symbol
PARD
Price
$0.00
Day change
0.00%
Market cap
$150.0
P/E ratio
-0.00x
52-week range
0.00001-0.0001
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Aeolus Pharmaceuticals, Inc. (AOLS)
  • Strategic Partners A/S (OZYMF)
  • PaxMedica, Inc. Common Stock (PXMD)
  • Q BioMed Inc. (QBIO)
  • RenovaCare, Inc. (RCAR)
  • Regenicin, Inc. (RGIN)
  • Scopus BioPharma Inc. (SCPS)
  • Vaxxinity, Inc. (VAXX)

Recent insider activity

  • PERRY MICHAEL S — S-Sale (1599 shares) on 2012-03-27
  • PERRY MICHAEL S — M-Exempt (2800 shares) on 2012-03-26
  • PERRY MICHAEL S — M-Exempt (2800 shares) on 2012-03-26
  • PERRY MICHAEL S — S-Sale (6346 shares) on 2012-02-16
  • PERRY MICHAEL S — M-Exempt (12019 shares) on 2012-02-15

Open Poniard Pharmaceuticals, Inc. (PARD) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.